Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para investigar la seguridad, farmacocinética y eficacia preliminar de la terapia IDE574 en participantes adultos con tumores sólidos avanzados

2 de noviembre de 2026 actualizado por: IDEAYA Biosciences

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

Tipo de estudio

Intervencionista

Inscripción (Estimado)

155

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • California
      • Santa Monica, California, Estados Unidos, 90404-2095
        • Activo, no reclutando
        • UCLA - Parkside Cancer Center
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510-3206
        • Reclutamiento
        • Yale School of Medicine - Cedar Street
        • Investigador principal:
          • Patricia LoRusso, MD
        • Contacto:
    • Florida
      • Plantation, Florida, Estados Unidos, 33322
        • Reclutamiento
        • Florida Clinical Trials Group
        • Investigador principal:
          • Harshad Amin, MD
        • Contacto:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322-1013
        • Reclutamiento
        • Winship Cancer Institute, Emory University
        • Investigador principal:
          • Shipra Gandhi, MD
        • Contacto:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110-1010
        • Reclutamiento
        • Washington University - Siteman Cancer Center
        • Investigador principal:
          • Faisal Fa'ak, MD
        • Contacto:
          • Pamela Coe
          • Número de teléfono: 314-747-7569
          • Correo electrónico: mpamela@wustl.edu
    • New Jersey
      • East Brunswick, New Jersey, Estados Unidos, 08816
        • Reclutamiento
        • START Astera, LLC
        • Investigador principal:
          • Bruno Fang, MD
        • Contacto:
    • New York
      • Lake Success, New York, Estados Unidos, 11042
        • Reclutamiento
        • START New York Long Island, LLC
        • Investigador principal:
          • Geraldine O'Sullivan Coyne, MD
        • Contacto:
      • New York, New York, Estados Unidos, 10032-3729
        • Activo, no reclutando
        • Columbia University Medical Center -161 Fort Washington
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • Reclutamiento
        • SCRI Oncology Partners - PPDS
        • Investigador principal:
          • Sarah Premji, MD
        • Contacto:
    • Texas
      • Austin, Texas, Estados Unidos, 78758
        • Reclutamiento
        • NEXT Texas LLC - Austin
        • Investigador principal:
          • Sheena Sahota, MD
        • Contacto:
      • Dallas, Texas, Estados Unidos, 75039
        • Reclutamiento
        • NEXT Texas LLC - Dallas
        • Investigador principal:
          • Faran Polani, MD
        • Contacto:
      • Fort Worth, Texas, Estados Unidos, 76104
        • Reclutamiento
        • START Dallas Fort Worth, LLC
        • Investigador principal:
          • Henry Xiong, MD
        • Contacto:
      • Houston, Texas, Estados Unidos, 77030-4009
        • Reclutamiento
        • MD Anderson Cancer Center
        • Investigador principal:
          • Timothy Yap, MD
        • Contacto:
      • Houston, Texas, Estados Unidos, 77054
        • Reclutamiento
        • NEXT Texas LLC - Houston
        • Investigador principal:
          • Jennifer Segar, MD
        • Contacto:
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • NEXT Texas LLC - San Antonio
        • Investigador principal:
          • David Sommerhalder, MD
        • Contacto:
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • Start San Antonio, LLC
        • Investigador principal:
          • Amita Patnaik, MD
        • Contacto:
    • Utah
      • West Valley City, Utah, Estados Unidos, 84119
        • Reclutamiento
        • START Mountain Region, LLC
        • Investigador principal:
          • William McKean, MD
        • Contacto:
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Reclutamiento
        • NEXT Virginia
        • Investigador principal:
          • Mohamad Salkeni, MD
        • Contacto:
    • K'alak'i T'bilisi
      • Batumi, K'alak'i T'bilisi, Georgia, 6000
        • Reclutamiento
        • High Technology Hospital MedCenter Ltd
        • Investigador principal:
          • Tamta Makharadze, MD
        • Contacto:
      • Tbilisi, K'alak'i T'bilisi, Georgia, 114
        • Reclutamiento
        • Pineo Medical Ecosystem
        • Contacto:
          • Nino Kekenadze
          • Número de teléfono: +995 593 660 940
          • Correo electrónico: Nkekenadze@pineo.ge
        • Investigador principal:
          • Mziuri Zakaraia, MD
      • Tbilisi, K'alak'i T'bilisi, Georgia, 112
        • Activo, no reclutando
        • LLC ARENSIA Exploratory Medicine
      • Tbilisi, K'alak'i T'bilisi, Georgia, 144
        • Activo, no reclutando
        • Geo Hospitals Multiprofile Medical Center Tbilisi
      • Tbilisi, K'alak'i T'bilisi, Georgia, 186
        • Activo, no reclutando
        • LLC Caucasus Medical Centre

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 99 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

Archival Tissue sample for testing

  • Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • Life expectancy of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with contraceptive/barrier requirements

Key Exclusion Criteria:

  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Monotherapy Dose Escalation (Part 1A)

Participants with the appropriate tumor types will be treated with escalating doses of IDE574

IDE574

Experimental: Monotherapy Dose Expansion (Part 1B)

Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

IDE574

Experimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

IDE574

Fulvestrant Injection

Experimental: Combination Dose Expansion (Part 2B)

Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

IDE574

Fulvestrant Injection

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Periodo de tiempo: Following the first dose of IDE574

incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

Following the first dose of IDE574
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Periodo de tiempo: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Periodo de tiempo: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Periodo de tiempo: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Periodo de tiempo: total study duration

Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Periodo de tiempo: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Periodo de tiempo: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Periodo de tiempo: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Periodo de tiempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Periodo de tiempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Periodo de tiempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Periodo de tiempo: total study duration
total study duration
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Periodo de tiempo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Periodo de tiempo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Periodo de tiempo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Periodo de tiempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Periodo de tiempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Periodo de tiempo: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Periodo de tiempo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Periodo de tiempo: total study duration
total study duration
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Periodo de tiempo: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Periodo de tiempo: total study duration
total study duration

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de marzo de 2026

Finalización primaria (Estimado)

31 de diciembre de 2029

Finalización del estudio (Estimado)

31 de enero de 2030

Fechas de registro del estudio

Enviado por primera vez

1 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de abril de 2026

Publicado por primera vez (Actual)

20 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

5 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • IDE574-001
  • 178299 (Otro identificador: Regulatory Agency Identifier Number (s))

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir